<p>Sutro Biopharma（纳斯达克代码：STRO - 获取免费报告）在周三发布的研究报告中，德意志银行的股票分析师将其目标价从 51.00 美元上调至 55.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。德意志银行的目标价意味着该股票相较于之前的收盘价有 128.98% 的潜在上涨空间。</p>
<p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
<p>其他一些股票研究分析师也对该股票发表了看法。Wedbush 在 12 月 2 日的报告中重新发布了 “中性” 评级，并将 Sutro Biopharma 的目标价设定为 100.00 美元（上调自 20.00 美元）。花旗集团在 1 月 20 日的研究报告中将 Sutro Biopharma 的评级提升至 “跑赢大盘”。富国银行在周二将 Sutro Biopharma 的评级从 “持平” 上调至 “超配”，并将其目标价从 8.00 美元提升至 27.00 美元。HC Wainwright 在周二将 Sutro Biopharma 的评级从 “中性” 上调至 “买入”，并将其目标价从 10.00 美元提升至 28.00 美元。最后，Citizens Jmp 在 1 月 20 日的报告中将 Sutro Biopharma 的评级从 “市场表现” 上调至 “市场跑赢”，并设定了 23.00 美元的目标价。六位投资分析师对该股票给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，平均目标价为 37.29 美元。</p>
<p><strong>查看我们关于 STRO 的最新报告</strong></p>
<h2>Sutro Biopharma 上涨 1.9%</h2>
<p>Sutro Biopharma 的股票在周三的午盘交易中上涨了 0.45 美元，达到 24.02 美元。该公司的股票交易量为 356,851 股，而其平均交易量为 155,858 股。Sutro Biopharma 的 52 周低点为 5.23 美元，52 周高点为 26.54 美元。该公司的 50 日移动平均价格为 18.39 美元，200 日移动平均价格为 12.68 美元。该股票的市值为 2.0441 亿美元，市盈率为-0.92，贝塔值为 1.47。</p>
<h2>对 Sutro Biopharma 的对冲基金看法</h2>
<p>大型投资者最近增加或减少了对该公司的持股。Bridgeway Capital Management LLC 在第三季度将其在 Sutro Biopharma 的持股增加了 232.6%。Bridgeway Capital Management LLC 目前拥有 42,900 股该公司的股票，价值 37,000 美元，此前在上个季度增持了 30,000 股。Invesco Ltd.在第一季度将其在 Sutro Biopharma 的持股增加了 137.8%。Invesco Ltd.目前拥有 92,139 股该公司的股票，价值 60,000 美元，此前在上个季度增持了 53,390 股。Cerity Partners LLC 在第二季度将其在 Sutro Biopharma 的持股增加了 169.9%。Cerity Partners LLC 目前拥有 105,437 股该公司的股票，价值 75,000 美元，此前在上个季度增持了 66,372 股。Qube Research &amp; Technologies Ltd 在第二季度购买了 Sutro Biopharma 的新股份，价值约 82,000 美元。最后，田纳西州财政部在第四季度购买了 Sutro Biopharma 的新股份，价值约 86,000 美元。机构投资者持有该公司 96.99% 的股票。</p>
<h2>Sutro Biopharma 新闻汇总</h2>
<p>以下是本周影响 Sutro Biopharma 的主要新闻：</p>
<ul>
<li>积极情绪：HC Wainwright 将 STRO 的评级从中性上调至买入，并将其目标价提高至 28 美元，突显分析师情绪改善，并为该股票提供买方支持。HC Wainwright 升级</li>
<li>积极情绪：富国银行将 STRO 的评级从持平上调至超配，并将其目标价提高至 27 美元，表明额外的机构支持和近期交易水平的上涨潜力。富国银行升级（覆盖）</li>
<li>积极情绪：临床催化剂：Sutro 报告在 STRO-004（组织因子 ADC）的 1 期试验中给药了三个队列，并保持在 2026 年中期报告初步临床数据的轨道上——这是一个短期的二元事件，如果数据积极，可能会显著推动股票。公司临床更新及 2025 财年业绩</li>
<li>中性情绪：HC Wainwright 发布了 2030 财年每股收益模型（预计未来几年将出现更大的负面每股收益），同时保持买入评级——该模型显示长期亏损，但该公司对管道进展的上行潜力进行估值。MarketBeat 摘要</li>
<li>中性情绪：本月的空头头寸报告显示数据异常（列为零股/0.0 天覆盖），因此没有明确的空头挤压信号来自报告的空头头寸。（数据似乎不可靠/未变化。）</li>
<li>消极情绪：2025 财年第四季度业绩：Sutro 报告的每股收益损失（5.39 美元）大于预期（4.66 美元），尽管收入超出预期（1165 万美元对 926 万美元）。公司仍处于亏损状态，利润率和股本回报率非常负面——提醒执行和现金消耗风险。财报发布</li>
</ul>
<h2>Sutro Biopharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于肿瘤学和免疫学领域新型生物药物候选者的发现和开发。该公司利用专有的无细胞蛋白合成平台 XpressCF™，设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化可能无法通过传统细胞表达系统实现的蛋白治疗。</p>
<p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了一条在不同阶段的免疫肿瘤候选者的管道。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Sutro Biopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RSTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RSTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
<p>在考虑 Sutro Biopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sutro Biopharma 并不在名单上。</p>
<p>虽然 Sutro Biopharma 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

STRO

<p>德意志银行股份公司已将 Sutro Biopharma（NASDAQ:STRO）的目标价格从 51.00 美元上调至 55.00 美元，维持 “买入” 评级。这个新目标暗示该股票相较于之前的收盘价有 128.98% 的潜在上涨空间。其他分析师也表现出积极的情绪，Wedbush、花旗集团和富国银行均对其进行了评级上调。Sutro Biopharma 的股票最近交易价格为 24.02 美元，反映出 1.9% 的上涨。该公司的市值为 2.0441 亿美元，正受到显著的机构关注，96.99% 的股份由大型投资者持有</p>

<p>Sutro Biopharma (NASDAQ:STRO - Get Free Report) had its price objective upped by stock analysts at Deutsche Bank Aktiengesellschaft from $51.00 to $55.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the stock. Deutsche Bank Aktiengesellschaft's target price would indicate a potential upside of 128.98% from the stock's previous close.</p>
<div class="lb-trans"><p>Sutro Biopharma（纳斯达克代码：STRO - 获取免费报告）在周三发布的研究报告中，德意志银行的股票分析师将其目标价从 51.00 美元上调至 55.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。德意志银行的目标价意味着该股票相较于之前的收盘价有 128.98% 的潜在上涨空间。</p>
</div><p>Get <strong>Sutro Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
</div><p>A number of other equities research analysts have also weighed in on the stock. Wedbush reissued a &#34;neutral&#34; rating and set a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. Citigroup raised shares of Sutro Biopharma to an &#34;outperform&#34; rating in a research note on Tuesday, January 20th. Wells Fargo &amp; Company upgraded shares of Sutro Biopharma from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and lifted their price target for the stock from $8.00 to $27.00 in a report on Tuesday. HC Wainwright raised shares of Sutro Biopharma from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and boosted their price objective for the stock from $10.00 to $28.00 in a research note on Tuesday. Finally, Citizens Jmp upgraded Sutro Biopharma from a &#34;market perform&#34; rating to a &#34;market outperform&#34; rating and set a $23.00 price objective for the company in a report on Tuesday, January 20th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $37.29.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也对该股票发表了看法。Wedbush 在 12 月 2 日的报告中重新发布了 “中性” 评级，并将 Sutro Biopharma 的目标价设定为 100.00 美元（上调自 20.00 美元）。花旗集团在 1 月 20 日的研究报告中将 Sutro Biopharma 的评级提升至 “跑赢大盘”。富国银行在周二将 Sutro Biopharma 的评级从 “持平” 上调至 “超配”，并将其目标价从 8.00 美元提升至 27.00 美元。HC Wainwright 在周二将 Sutro Biopharma 的评级从 “中性” 上调至 “买入”，并将其目标价从 10.00 美元提升至 28.00 美元。最后，Citizens Jmp 在 1 月 20 日的报告中将 Sutro Biopharma 的评级从 “市场表现” 上调至 “市场跑赢”，并设定了 23.00 美元的目标价。六位投资分析师对该股票给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，平均目标价为 37.29 美元。</p>
</div><p><strong>Check Out Our Latest Report on STRO</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 STRO 的最新报告</strong></p>
</div><h2>Sutro Biopharma Trading Up 1.9%</h2>
<div class="lb-trans"><h2>Sutro Biopharma 上涨 1.9%</h2>
</div><p>Sutro Biopharma stock traded up $0.45 during midday trading on Wednesday, reaching $24.02. The company's stock had a trading volume of 356,851 shares, compared to its average volume of 155,858. Sutro Biopharma has a 52 week low of $5.23 and a 52 week high of $26.54. The business has a 50-day moving average price of $18.39 and a 200-day moving average price of $12.68. The stock has a market cap of $204.41 million, a PE ratio of -0.92 and a beta of 1.47.</p>
<div class="lb-trans"><p>Sutro Biopharma 的股票在周三的午盘交易中上涨了 0.45 美元，达到 24.02 美元。该公司的股票交易量为 356,851 股，而其平均交易量为 155,858 股。Sutro Biopharma 的 52 周低点为 5.23 美元，52 周高点为 26.54 美元。该公司的 50 日移动平均价格为 18.39 美元，200 日移动平均价格为 12.68 美元。该股票的市值为 2.0441 亿美元，市盈率为-0.92，贝塔值为 1.47。</p>
</div><h2>Hedge Funds Weigh In On Sutro Biopharma</h2>
<div class="lb-trans"><h2>对 Sutro Biopharma 的对冲基金看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. Bridgeway Capital Management LLC boosted its holdings in Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company's stock worth $37,000 after acquiring an additional 30,000 shares during the last quarter. Invesco Ltd. boosted its holdings in Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company's stock worth $60,000 after purchasing an additional 53,390 shares during the last quarter. Cerity Partners LLC boosted its holdings in Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company's stock worth $75,000 after purchasing an additional 66,372 shares during the last quarter. Qube Research &amp; Technologies Ltd bought a new stake in Sutro Biopharma in the 2nd quarter worth about $82,000. Finally, State of Tennessee Department of Treasury bought a new stake in Sutro Biopharma in the 4th quarter worth about $86,000. Institutional investors own 96.99% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。Bridgeway Capital Management LLC 在第三季度将其在 Sutro Biopharma 的持股增加了 232.6%。Bridgeway Capital Management LLC 目前拥有 42,900 股该公司的股票，价值 37,000 美元，此前在上个季度增持了 30,000 股。Invesco Ltd.在第一季度将其在 Sutro Biopharma 的持股增加了 137.8%。Invesco Ltd.目前拥有 92,139 股该公司的股票，价值 60,000 美元，此前在上个季度增持了 53,390 股。Cerity Partners LLC 在第二季度将其在 Sutro Biopharma 的持股增加了 169.9%。Cerity Partners LLC 目前拥有 105,437 股该公司的股票，价值 75,000 美元，此前在上个季度增持了 66,372 股。Qube Research &amp; Technologies Ltd 在第二季度购买了 Sutro Biopharma 的新股份，价值约 82,000 美元。最后，田纳西州财政部在第四季度购买了 Sutro Biopharma 的新股份，价值约 86,000 美元。机构投资者持有该公司 96.99% 的股票。</p>
</div><h2>Sutro Biopharma News Roundup</h2>
<div class="lb-trans"><h2>Sutro Biopharma 新闻汇总</h2>
</div><p>Here are the key news stories impacting Sutro Biopharma this week:</p>
<div class="lb-trans"><p>以下是本周影响 Sutro Biopharma 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its price target to $28, highlighting improved analyst sentiment and providing buy-side support for the stock. HC Wainwright upgrade</li>
<li>Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and lifted its price target to $27, signaling additional institutional support and near‑term upside vs. recent trade levels. Wells Fargo upgrade (coverage)</li>
<li>Positive Sentiment: Clinical catalyst: Sutro reported dosing three cohorts in the Phase 1 trial of STRO‑004 (a Tissue Factor ADC) and remains on track to report initial clinical data in mid‑2026 — a near‑term binary event that could materially move the stock if data are positive. Company clinical update &amp; FY2025 results</li>
<li>Neutral Sentiment: HC Wainwright published FY2030 EPS modeling (projecting larger negative EPS out-year) while keeping a Buy rating — the model shows long-term losses but the firm is valuing upside from pipeline progress. MarketBeat summary</li>
<li>Neutral Sentiment: Short‑interest reports this month show data anomalies (listed as zero shares / 0.0 days to cover), so there’s no clear short‑squeeze signal from reported short interest. (Data appears unreliable/unchanged.)</li>
<li>Negative Sentiment: Q4/FY2025 results: Sutro reported a larger-than-expected EPS loss of ($5.39) vs. consensus ($4.66) despite revenue beating estimates ($11.65M vs. $9.26M). Company remains unprofitable with very negative margins and ROE — a reminder of execution and cash‑burn risks. Earnings release</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 将 STRO 的评级从中性上调至买入，并将其目标价提高至 28 美元，突显分析师情绪改善，并为该股票提供买方支持。HC Wainwright 升级</li>
<li>积极情绪：富国银行将 STRO 的评级从持平上调至超配，并将其目标价提高至 27 美元，表明额外的机构支持和近期交易水平的上涨潜力。富国银行升级（覆盖）</li>
<li>积极情绪：临床催化剂：Sutro 报告在 STRO-004（组织因子 ADC）的 1 期试验中给药了三个队列，并保持在 2026 年中期报告初步临床数据的轨道上——这是一个短期的二元事件，如果数据积极，可能会显著推动股票。公司临床更新及 2025 财年业绩</li>
<li>中性情绪：HC Wainwright 发布了 2030 财年每股收益模型（预计未来几年将出现更大的负面每股收益），同时保持买入评级——该模型显示长期亏损，但该公司对管道进展的上行潜力进行估值。MarketBeat 摘要</li>
<li>中性情绪：本月的空头头寸报告显示数据异常（列为零股/0.0 天覆盖），因此没有明确的空头挤压信号来自报告的空头头寸。（数据似乎不可靠/未变化。）</li>
<li>消极情绪：2025 财年第四季度业绩：Sutro 报告的每股收益损失（5.39 美元）大于预期（4.66 美元），尽管收入超出预期（1165 万美元对 926 万美元）。公司仍处于亏损状态，利润率和股本回报率非常负面——提醒执行和现金消耗风险。财报发布</li>
</ul>
</div><h2>Sutro Biopharma Company Profile</h2>
<div class="lb-trans"><h2>Sutro Biopharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.</p>
<div class="lb-trans"><p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于肿瘤学和免疫学领域新型生物药物候选者的发现和开发。该公司利用专有的无细胞蛋白合成平台 XpressCF™，设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化可能无法通过传统细胞表达系统实现的蛋白治疗。</p>
</div><p>Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了一条在不同阶段的免疫肿瘤候选者的管道。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Sutro Biopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Sutro Biopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RSTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=STRO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sutro Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
</div><p>Before you consider Sutro Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sutro Biopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sutro Biopharma 并不在名单上。</p>
</div><p>While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sutro Biopharma 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

德意志银行股份公司对 Sutro Biopharma（NASDAQ:STRO）股票价格发布了乐观的预测